We use cookies to optimise this website and continuously update it according to your needs. Please click on "Configure" for detailed information on the use of cookies on this website. If you click "Yes, I agree", cookies will be activated. If you do not want cookies to be activated, you can adjust your settings by clicking on "Configure". The settings can be changed at any time under "Cookies".
STOCKHOLM, February 16, 2018 – Elekta (EKTA-B.ST) will publish its Q3 report for 2017/18 on March 2, as per:
To take part in the conference call, please dial in about five minutes in advance.
The telephone conference will also be broadcasted live online, through the following link (however, in order to ask questions it is necessary to call in): http://event.on24.com/wcc/r/1610945-1/DED93131C299D012C6AE58D8B0CA96B6?partnerref=rss-events
# # #
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm www.elekta.com
Johan Andersson, Director Investor Relations, Elekta AB.
Tel: +46 702 100 451,
E-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communications, Elekta AB
Tel: +46 722 215 017,
E-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time